Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Boston Scientific (BSX) upgraded to Buy from Hold at Argus by analyst David Toung, who believes that the company reported "strong" Q2 sales and is gaining share. 2. WEX Inc. (WEX) upgraded to Outperform from Underperform at CLSA by analyst Tom McCrohan who increased his average fuel price outlook, which resulted in an increase in earnings contribution of approximately 30c per share for both 2017 and 2018. Additionally, the analyst said management is beginning to implement higher late fees on its small business clients, which can unlock 90c per share of additional earnings power as small fleet customers incur higher late fees on overdue balances. 3. Nomura (NMR) upgraded to Hold from Underperform at Jefferies by analyst Makarim Salman, who still cautions investors not to "chase the momentum" following the company's positive Q1 earnings. 4. Seacoast Banking (SBCF) upgraded to Outperform from Market Perform at Keefe Bruyette by analyst Jefferson Harralson, who thinks the company is about to "ramp to a meaningfully higher profitability" following its efficiency improvements. 5. Randgold (GOLD) upgraded to Buy from Hold at Canaccord, citing valuation following its Q2 results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

RBC Capital raised the firm's price target on Boston Scientific to $82 from $78 and keeps an Outperform rating on the shares. Given the company's Q1 momentum on seales and earnings, along with its new product ramp, the management's updated FY24 guidance is likely "conservative" despite easier comps, the analyst tells investors in a research note. RBC adds that the stock is its top pick in the Sector based on its "industry-leading growth profile".

Evercore ISI analyst Vijay Kumar raised the firm's price target on Boston Scientific to $78 from $72 and keeps an Outperform rating on the shares as the firm said the company reported "solid results and there wasn't much to pick on." While EP franchise acceleration driven by Farapulse PFA launch "is generally well known" by the Street, the firm says it doesn't think "anyone expected ~86% US growth and ~72% International growth."

Consensus for FY24 EPS is $16.25. Raises FY24 revenue view to $2.73B-$2.77B from $2.70B-$2.74B, consensus $2.73B.

Reports Q1 revenue $652.7M, consensus $654.7M. "WEX delivered impressive financial results in the first quarter, including record first quarter revenue, marking a strong start to 2024 and reinforcing our ability to drive robust performance in any macroeconomic environment," said CEO Melissa Smith. "Moreover, we continued to execute against our strategic initiatives. During the quarter, we made great progress integrating our recent acquisitions, launched the pilot for an enhanced acceptance offering for our North American Mobility customers, and continued to drive innovation to expand our customer value proposition. We are also laser-focused on leveraging technology and AI to improve efficiency and further enhance our offerings. Looking ahead, I remain confident in our ability to drive growth across the business in the near- and long-term."

Baird analyst David Rescott raised the firm's price target on Boston Scientific to $84 from $79 and keeps an Outperform rating on the shares. The firm noted its 1Q24 revenue/adjusted EPS beat was the biggest over the past several years and one of the most compelling in diversified LGCP MedTech.

WEX (WEX) announced that it has reached a new long-term agreement with Booking.com (BKNG), effective April 2024. This agreement distinguishes WEX as Booking.com's preferred virtual card provider as it continues providing WEX payment solutions in support of Booking.com's payments vision to make buying and selling travel-related products and services easier for everyone. "With more than 800,000 active customer relationships worldwide, WEX is proud to work with eight of the top ten online travel agencies globally, including Booking.com," said Carlos Carriedo, WEX's Chief Operating Officer, International. "Building on years of working together, we remain committed to delivering WEX's deep expertise in both payments and travel, as well as the reliability of our technology platform, to help Booking.com power its B2B travel payment activities 24/7 and 365 days/year at scale, globally." Booking.com first became a WEX customer in 2013. Over a decade later, WEX now processes payments for Booking.com across the world.

Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here